Cell-specific RNA interference by peptide-inhibited-peptidase-activated siRNAs

Area of Science:

• Molecular Biology
• Gene Regulation
• Biotechnology

Background:

• Short interfering RNAs (siRNAs) are crucial for gene expression manipulation in mammalian systems.
• Developing cell-specific RNA interference (RNAi) is essential for therapeutic applications of siRNAs.
• Previous strategies have focused on enhancing siRNA targeting for improved specificity.

Purpose of the Study:

• To investigate the efficacy of peptide-inhibited siRNAs for cell-specific gene silencing.
• To evaluate the therapeutic potential of peptide-inhibited siRNAs activated by cell-specific peptidases.
• To determine if this approach can selectively reduce gene expression in target cells.

Main Methods:

• Chemically synthesized siRNAs were modified with peptides to inhibit activity until cleaved by cell-specific peptidases.
• Assessed RNA interference (RNAi) induction in JEG-3 cells expressing caspase-4 versus HEK cells lacking the enzyme.
• Measured the reduction of Green Fluorescent Protein (GFP) and Signal Transducer and Activator of Transcription (STAT)-3 gene expression.
• Evaluated the impact of STAT3 gene reduction on cell proliferation in JEG-3 cells.

Main Results:

• Peptide-inhibited siRNAs were activated by cleavage in target cells, inducing RNAi in a cell-specific manner.
• Selective reduction of GFP and STAT3 gene expression was observed in JEG-3 cells, but not in HEK cells.
• STAT3 gene silencing in JEG-3 cells led to a significant decrease in cell proliferation.
• The peptide-inhibited siRNA approach demonstrated enhanced cell specificity compared to conventional siRNAs.

Conclusions:

• Peptide-inhibited siRNAs offer a novel strategy for achieving highly specific gene silencing.
• This method enhances the therapeutic utility of siRNAs by enabling targeted delivery and activation.
• The findings suggest promising new avenues for siRNA-based therapeutics with improved safety and efficacy profiles.